Gilead Sciences, Inc.

Pacific Biosciences of California, Inc.

Epitherapeutics Aps

Ying Yang

Thomas Boesen

Marc A Labelle

Farman Ullah

Ramkrishna Reddy Vakiti

Neerja Saraswat

Stephen T Yue

Erik Miller

Satwik Kamtekar

Jeremiah Hanes

Lubomir Sebo

Mukund Mehrotra

Qasim Khan

Leewin Chern

Utpal Sharma

Thomas Linsky

Cyril Cook

Dastagiri Dudekula

Rui Zhang

Compositions comprising covalently modified and mutated biotin-binding proteins, particularly biotin-binding proteins having a negative charge at physiological pH, are provided. Methods of producing such proteins are also provided, as are methods of immobilizing, sequencing, and making nucleic acids employing such proteins.

Modified biotin-binding proteins for immobilization

The present application relates to compounds being of Formula (I), (II), (III), (IV), (V), (VI), (IIIa), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), and (IIIg). Compounds of Formula (I) have the structure: wherein Q, R, R, R, M, A and Y are as defined herein. The compounds of the application can modulate the activity of histone demethylases (HDMEs), and can be useful for the prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, e.g., cancer.

Compounds and methods for inhibiting histone demethylases

Compounds of the form In which Q is selected from &#x2014;CH&#x2550;NR, &#x2014;W, &#x2014;CHNHR, &#x2014;CH&#x2550;O and &#x2014;CH(OR)capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.

Inhibitors of histone demethylases

Growing community of inventors

Fremont, CA, United States of America

Ying Yang